Hitting the bull's eye: Targeting HMGA1 in cancer stem cells

Breann L. Yanagisawa, Linda M Smith Resar

Research output: Contribution to journalArticle

Abstract

Emerging evidence suggests that when cancer cells hijack normal stem cell properties, they acquire the ability to invade, metastasize to distant sites and evade therapy. Thus, eliminating cancer cells with stem cell properties, or cancer stem cells, is of prime importance for the successful treatment of cancer, regardless of the tissue of origin. Previous efforts to target cancer stem cells (CSCs), however, have been largely unsuccessful. Recent studies led to the discovery of a novel role for the high mobility group A1 (HMGA1) protein as a master regulator in both CSCs and normal embryonic stem cells. Here, we present exciting new work unveiling HMGA1 as a promising target for therapies directed at eradicating CSCs.

Original languageEnglish (US)
Pages (from-to)23-30
Number of pages8
JournalExpert Review of Anticancer Therapy
Volume14
Issue number1
DOIs
StatePublished - Jan 2014

Fingerprint

Neoplastic Stem Cells
Stem Cells
High Mobility Group Proteins
Neoplasms
Embryonic Stem Cells
Therapeutics

Keywords

  • cancer stem cells
  • embryonic stem cells
  • epithelial-mesenchymal transition
  • high mobility group A1 protein
  • HMGA1

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Oncology

Cite this

Hitting the bull's eye : Targeting HMGA1 in cancer stem cells. / Yanagisawa, Breann L.; Smith Resar, Linda M.

In: Expert Review of Anticancer Therapy, Vol. 14, No. 1, 01.2014, p. 23-30.

Research output: Contribution to journalArticle

@article{b17ae15a8ceb4c2ca9c82ad30bf1cb9a,
title = "Hitting the bull's eye: Targeting HMGA1 in cancer stem cells",
abstract = "Emerging evidence suggests that when cancer cells hijack normal stem cell properties, they acquire the ability to invade, metastasize to distant sites and evade therapy. Thus, eliminating cancer cells with stem cell properties, or cancer stem cells, is of prime importance for the successful treatment of cancer, regardless of the tissue of origin. Previous efforts to target cancer stem cells (CSCs), however, have been largely unsuccessful. Recent studies led to the discovery of a novel role for the high mobility group A1 (HMGA1) protein as a master regulator in both CSCs and normal embryonic stem cells. Here, we present exciting new work unveiling HMGA1 as a promising target for therapies directed at eradicating CSCs.",
keywords = "cancer stem cells, embryonic stem cells, epithelial-mesenchymal transition, high mobility group A1 protein, HMGA1",
author = "Yanagisawa, {Breann L.} and {Smith Resar}, {Linda M}",
year = "2014",
month = "1",
doi = "10.1586/14737140.2013.859988",
language = "English (US)",
volume = "14",
pages = "23--30",
journal = "Expert Review of Anticancer Therapy",
issn = "1473-7140",
publisher = "Expert Reviews Ltd.",
number = "1",

}

TY - JOUR

T1 - Hitting the bull's eye

T2 - Targeting HMGA1 in cancer stem cells

AU - Yanagisawa, Breann L.

AU - Smith Resar, Linda M

PY - 2014/1

Y1 - 2014/1

N2 - Emerging evidence suggests that when cancer cells hijack normal stem cell properties, they acquire the ability to invade, metastasize to distant sites and evade therapy. Thus, eliminating cancer cells with stem cell properties, or cancer stem cells, is of prime importance for the successful treatment of cancer, regardless of the tissue of origin. Previous efforts to target cancer stem cells (CSCs), however, have been largely unsuccessful. Recent studies led to the discovery of a novel role for the high mobility group A1 (HMGA1) protein as a master regulator in both CSCs and normal embryonic stem cells. Here, we present exciting new work unveiling HMGA1 as a promising target for therapies directed at eradicating CSCs.

AB - Emerging evidence suggests that when cancer cells hijack normal stem cell properties, they acquire the ability to invade, metastasize to distant sites and evade therapy. Thus, eliminating cancer cells with stem cell properties, or cancer stem cells, is of prime importance for the successful treatment of cancer, regardless of the tissue of origin. Previous efforts to target cancer stem cells (CSCs), however, have been largely unsuccessful. Recent studies led to the discovery of a novel role for the high mobility group A1 (HMGA1) protein as a master regulator in both CSCs and normal embryonic stem cells. Here, we present exciting new work unveiling HMGA1 as a promising target for therapies directed at eradicating CSCs.

KW - cancer stem cells

KW - embryonic stem cells

KW - epithelial-mesenchymal transition

KW - high mobility group A1 protein

KW - HMGA1

UR - http://www.scopus.com/inward/record.url?scp=84893059106&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84893059106&partnerID=8YFLogxK

U2 - 10.1586/14737140.2013.859988

DO - 10.1586/14737140.2013.859988

M3 - Article

C2 - 24410339

AN - SCOPUS:84893059106

VL - 14

SP - 23

EP - 30

JO - Expert Review of Anticancer Therapy

JF - Expert Review of Anticancer Therapy

SN - 1473-7140

IS - 1

ER -